European Regulators Approve Sales of First Artificial Heart
- CE mark in 10 years ‘a record’ but production is complex: CEO
- Artificial heart has blockbuster sales potential: Portzamparc
A Carmat employee shows an auto-regulating, bioprosthetic artificial heart.
Photographer: Bertrand Guay/AFP/Getty Images
This article is for subscribers only.
Shares in Carmat SA posted their biggest gain in more than seven years after the company got approval to sell the first-ever total artificial heart in Europe, the culmination of a 27-year effort that began with a pitch from a French cardiac surgeon to an aerospace company.
The stock climbed 34% to 32.05 euros at 11:29 a.m. in Paris after rising as much as 50%, its steepest intraday gain since May 2013. Carmat shares have advanced 66% this year, giving the company a market value of about 407 million euros ($496 million).